DIABETES Breaking news! Rosiglitazone and cardiovascular risk

被引：10
|
作者：
Kaul, Sanjay [1 ]
Diamond, George A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA
来源：
NATURE REVIEWS CARDIOLOGY | 2010年 / 7卷 / 12期
关键词：
MYOCARDIAL-INFARCTION; HEART-FAILURE; DEATH;
D O I：
10.1038/nrcardio.2010.160
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In the past 3 years, several studies have reignited the controversy regarding the cardiovascular risk associated with the use of rosiglitazone. Until a prospective, well-controlled, randomized clinical trial is performed to adjudicate the issue definitively, physicians should be free to exercise clinical judgment, and weigh the comparative risks and benefits of agents such as rosiglitazone on a case-by-case basis.
引用
收藏
页码：670 / 672
页数：4
相关论文
共 50 条
  • [1] Breaking news! Rosiglitazone and cardiovascular risk
    Sanjay Kaul
    George A. Diamond
    Nature Reviews Cardiology, 2010, 7 : 670 - 672
  • [2] Rosiglitazone and cardiovascular risk
    Psaty, Bruce M.
    Furberg, Curt D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24): : 2522 - 2524
  • [3] Rosiglitazone and Cardiovascular Risk
    Kaul, Sanjay
    Diamond, George A.
    CURRENT ATHEROSCLEROSIS REPORTS, 2008, 10 (05) : 398 - 404
  • [4] Rosiglitazone and Cardiovascular Risk
    Kintscher, U.
    KARDIOLOGE, 2007, 1 (02): : 139 - 141
  • [5] Rosiglitazone and cardiovascular risk
    Sanjay Kaul
    George A. Diamond
    Current Atherosclerosis Reports, 2008, 10 : 398 - 404
  • [6] Rosiglitazone and cardiovascular risk - Reply
    Psaty, Bruce M.
    Furberg, Curt D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09): : 940 - 940
  • [7] Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus
    Irons, BK
    Greene, RS
    Mazzolini, TA
    Edwards, KL
    Sleeper, RB
    PHARMACOTHERAPY, 2006, 26 (02): : 168 - 181
  • [8] Cardiovascular risk of rosiglitazone: another perspective
    Waksman, Javier C.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2008, 60 (12) : 1573 - 1582
  • [9] Rosiglitazone and the Risk of Adverse Cardiovascular Outcomes
    Winterstein, A. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) : 776 - 778
  • [10] The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk
    Yee, M. S.
    Pavitt, D. V.
    Dhanjil, S.
    Godsland, I. F.
    Richmond, W.
    Johnston, D. G.
    DIABETIC MEDICINE, 2010, 27 (12) : 1392 - 1400
12345